178 related articles for article (PubMed ID: 35114584)
1. Identification through action potential clamp of proarrhythmic consequences of the short QT syndrome T618I hERG 'hotspot' mutation.
Du C; Zhang H; Harmer SC; Hancox JC
Biochem Biophys Res Commun; 2022 Mar; 596():49-55. PubMed ID: 35114584
[TBL] [Abstract][Full Text] [Related]
2. Action potential clamp characterization of the S631A hERG mutation associated with short QT syndrome.
Butler A; Zhang Y; Stuart AG; Dempsey CE; Hancox JC
Physiol Rep; 2018 Sep; 6(17):e13845. PubMed ID: 30175559
[TBL] [Abstract][Full Text] [Related]
3. Action potential clamp and pharmacology of the variant 1 Short QT Syndrome T618I hERG K⁺ channel.
El Harchi A; Melgari D; Zhang YH; Zhang H; Hancox JC
PLoS One; 2012; 7(12):e52451. PubMed ID: 23300672
[TBL] [Abstract][Full Text] [Related]
4. Comparative effects of the short QT N588K mutation at 37 degrees C on hERG K+ channel current during ventricular, Purkinje fibre and atrial action potentials: an action potential clamp study.
McPate MJ; Zhang H; Adeniran I; Cordeiro JM; Witchel HJ; Hancox JC
J Physiol Pharmacol; 2009 Mar; 60(1):23-41. PubMed ID: 19439805
[TBL] [Abstract][Full Text] [Related]
5. Functional and pharmacological characterization of an S5 domain hERG mutation associated with short QT syndrome.
Butler A; Zhang Y; Stuart AG; Dempsey CE; Hancox JC
Heliyon; 2019 Apr; 5(4):e01429. PubMed ID: 31049424
[TBL] [Abstract][Full Text] [Related]
6. A novel mutation in the KCNH2 gene associated with short QT syndrome.
Sun Y; Quan XQ; Fromme S; Cox RH; Zhang P; Zhang L; Guo D; Guo J; Patel C; Kowey PR; Yan GX
J Mol Cell Cardiol; 2011 Mar; 50(3):433-41. PubMed ID: 21130771
[TBL] [Abstract][Full Text] [Related]
7. Serine mutation of a conserved threonine in the hERG K
Al-Moubarak E; Zhang Y; Dempsey CE; Zhang H; Harmer SC; Hancox JC
Biochem Biophys Res Commun; 2020 Jun; 526(4):1085-1091. PubMed ID: 32321643
[TBL] [Abstract][Full Text] [Related]
8. Modulation of I(Kr) inactivation by mutation N588K in KCNH2: a link to arrhythmogenesis in short QT syndrome.
Cordeiro JM; Brugada R; Wu YS; Hong K; Dumaine R
Cardiovasc Res; 2005 Aug; 67(3):498-509. PubMed ID: 16039272
[TBL] [Abstract][Full Text] [Related]
9. The Phenotypic Spectrum of a Mutation Hotspot Responsible for the Short QT Syndrome.
Hu D; Li Y; Zhang J; Pfeiffer R; Gollob MH; Healey J; Harrell DT; Makita N; Abe H; Sun Y; Guo J; Zhang L; Yan G; Mah D; Walsh EP; Leopold HB; Giustetto C; Gaita F; Zienciuk-Krajka A; Mazzanti A; Priori SG; Antzelevitch C; Barajas-Martinez H
JACC Clin Electrophysiol; 2017 Jul; 3(7):727-743. PubMed ID: 29759541
[TBL] [Abstract][Full Text] [Related]
10. Electrophysiological characterization of the modified hERG
Zhang Y; Dempsey CE; Hancox JC
Physiol Rep; 2020 Oct; 8(20):e14568. PubMed ID: 33091232
[TBL] [Abstract][Full Text] [Related]
11. Interactions between amiodarone and the hERG potassium channel pore determined with mutagenesis and in silico docking.
Zhang Y; Colenso CK; El Harchi A; Cheng H; Witchel HJ; Dempsey CE; Hancox JC
Biochem Pharmacol; 2016 Aug; 113():24-35. PubMed ID: 27256139
[TBL] [Abstract][Full Text] [Related]
12. Clemastine, a conventional antihistamine, is a high potency inhibitor of the HERG K+ channel.
Ridley JM; Milnes JT; Hancox JC; Witchel HJ
J Mol Cell Cardiol; 2006 Jan; 40(1):107-18. PubMed ID: 16288909
[TBL] [Abstract][Full Text] [Related]
13. Increased vulnerability of human ventricle to re-entrant excitation in hERG-linked variant 1 short QT syndrome.
Adeniran I; McPate MJ; Witchel HJ; Hancox JC; Zhang H
PLoS Comput Biol; 2011 Dec; 7(12):e1002313. PubMed ID: 22194679
[TBL] [Abstract][Full Text] [Related]
14. Suppression of the hERG potassium channel response to premature stimulation by reduction in extracellular potassium concentration.
Melgari D; Du C; El Harchi A; Zhang Y; Hancox JC
Physiol Rep; 2014 Oct; 2(10):. PubMed ID: 25318749
[TBL] [Abstract][Full Text] [Related]
15. Tbx20 controls the expression of the KCNH2 gene and of hERG channels.
Caballero R; Utrilla RG; Amorós I; Matamoros M; Pérez-Hernández M; Tinaquero D; Alfayate S; Nieto-Marín P; Guerrero-Serna G; Liu QH; Ramos-Mondragón R; Ponce-Balbuena D; Herron T; Campbell KF; Filgueiras-Rama D; Peinado R; López-Sendón JL; Jalife J; Delpón E; Tamargo J
Proc Natl Acad Sci U S A; 2017 Jan; 114(3):E416-E425. PubMed ID: 28049825
[TBL] [Abstract][Full Text] [Related]
16. Ranolazine inhibition of hERG potassium channels: drug-pore interactions and reduced potency against inactivation mutants.
Du C; Zhang Y; El Harchi A; Dempsey CE; Hancox JC
J Mol Cell Cardiol; 2014 Sep; 74(100):220-30. PubMed ID: 24877995
[TBL] [Abstract][Full Text] [Related]
17. New aspects of HERG K⁺ channel function depending upon cardiac spatial heterogeneity.
Zhang P; Guan P; Bai XL; Song ZP
PLoS One; 2014; 9(1):e72181. PubMed ID: 24475014
[TBL] [Abstract][Full Text] [Related]
18. Transgenic short-QT syndrome 1 rabbits mimic the human disease phenotype with QT/action potential duration shortening in the atria and ventricles and increased ventricular tachycardia/ventricular fibrillation inducibility.
Odening KE; Bodi I; Franke G; Rieke R; Ryan de Medeiros A; Perez-Feliz S; Fürniss H; Mettke L; Michaelides K; Lang CN; Steinfurt J; Pantulu ND; Ziupa D; Menza M; Zehender M; Bugger H; Peyronnet R; Behrends JC; Doleschall Z; Zur Hausen A; Bode C; Jolivet G; Brunner M
Eur Heart J; 2019 Mar; 40(10):842-853. PubMed ID: 30496390
[TBL] [Abstract][Full Text] [Related]
19. In silico assessment of the effects of quinidine, disopyramide and E-4031 on short QT syndrome variant 1 in the human ventricles.
Luo C; Wang K; Zhang H
PLoS One; 2017; 12(6):e0179515. PubMed ID: 28632743
[TBL] [Abstract][Full Text] [Related]
20. The Susceptibilities of Human Ether-à-Go-Go-Related Gene Channel with the G487R Mutation to Arrhythmogenic Factors.
Hisajima N; Hata Y; Kinoshita K; Fukushima T; Nishida N; Kano M; Tabata T
Biol Pharm Bull; 2015; 38(5):781-4. PubMed ID: 25947924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
